Cariprazine Hcl
Brand name: Vraylar
Rank #55 of 500 drugs by total cost
$329.1M
Total Cost
226,854
Total Claims
$329.1M
Total Cost
7,405
Prescribers
$1,451
Cost per Claim
12,045
Beneficiaries
237,038
30-Day Fills
$44K
Avg Cost/Provider
31
Avg Claims/Provider
About Cariprazine Hcl
Cariprazine Hcl (sold as Vraylar) was prescribed 226,854 times by 7,405 Medicare Part D providers in 2023, costing the program $329.1M. At $1,451 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 52 | Upadacitinib (Rinvoq) | $346.0M | 51,469 |
| 53 | Abiraterone Acetate (Abiraterone Acetate) | $345.0M | 122,643 |
| 54 | Icosapent Ethyl (Vascepa) | $334.9M | 692,252 |
| 55 | Cariprazine Hcl (Vraylar) | $329.1M | 226,854 |
| 56 | Albuterol Sulfate (Albuterol Sulfate Hfa) | $312.2M | 7,904,120 |
| 57 | Rifaximin (Xifaxan) | $310.0M | 111,328 |
| 58 | Sitagliptin Phos/Metformin Hcl (Janumet) | $302.2M | 329,315 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology